Home > Market > Market Stats > sun-pharmaceutical-industries
  1. S&P BSE SENSEX
    57,200.23 -76.71 (-0.13%)
  1. NIFTY 50 D
    Delayed by 15 mins

    17,101.95 -8.2 (-0.05%)
  1. NIFTY BANK D
    Delayed by 15 mins

    37,689.4 -292.7 (-0.77%)
  1. S&P BSE MIDCAP
    24,186.73 244.63 (1.02%)
  1. GOLD
    47,640 0 (0.00%)
  1. SILVER
    61,012 0 (0.00%)

SUN.BO Sun Pharmaceutical Industries

827.25 15.05 (1.85%) 28 JAN 2022 10:17:35
827.35 15.25 (1.88%) 28 Jan 2022 10:26:59
Add Stock to Portfolio / Watchlist on mint Genie + Add Stock
  1. Open price812.2
  2. Prev close812.2
  3. Day high842.5
  4. Day low812.2
  5. 52 week high871.0
  6. 52 week low550.7
  7. Bid quantity0.0
  8. Volume477516
  1. Open price816
  2. Prev close812.1
  3. Day high842.9
  4. Day low812.1
  5. 52 week high871
  6. 52 week low550.4
  7. Bid quantity827.35
  8. Volume5073701
FINANCIALS
Standalone
Revenue
33,498.14
Total Revenue
33,498.14
Costof Revenue Total
9,885.42
Gross Profit
23,612.72
Selling/ General/ Admin Expenses Total
14,344.76
Depreciation/ Amortization
2,079.95
Unusual Expense( Income)
4,321.69
Other Operating Expenses Total
526.81
Total Operating Expense
31,158.63
Operating Income
2,339.51
Interest Inc( Exp) Net- Non- Op Total
3,787
Gain( Loss)on Saleof Assets
138.8
Other Net
67.28
Net Income Before Taxes
2,799.37
Provisionfor Income Taxes
514.69
Net Income After Taxes
2,284.68
Minority Interest
631.47
Equity In Affiliates
-123.3
Net Income Before Extra Items
2,903.82
Net Income
2,903.82
Income Availableto Com Excl Extra Ord
2,903.82
Income Availableto Com Incl Extra Ord
2,903.82
Diluted Net Income
2,903.82
Diluted Weighted Average Shares
239.93
Diluted EPS Excluding Extra Ord Items
12.1
DPS- Common Stock Primary Issue
7.5
Diluted Normalized EPS
26.76
COMPANY INFORMATION
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
Industry Biotechnology & Drugs
ISIN INE044A01036
BSE code 524715
NSE code SUNPHARMA
Chief Financial OfficerC. S.   Muralidharan
Chief Executive Officer - Taro Pharmaceutical Industries LimitedUday   Baldota
Chief Executive Officer, North AmericaAbhay   Gandhi
Chief Executive Officer - India BusinessKirti   Ganorkar
Chief Executive Officer - API BusinessAnilkumar   Jain
Executive Vice President, Global Head - QualityJila   Breeze
Executive Vice President, Head - Research and Development, USPradeep   Sanghvi
Executive Vice President, Head - Emerging Markets, Head - Global Generics, Research and Development, Business DevelopmentAalok   Shanghvi
Executive Vice President - Sun Global OperationsDavinder   Singh
Senior Vice President, Head of Human ResourcesSapna   Purohit
NEWS - COMPANIES
View More News
×
Edit Profile
Get alerts on WhatsApp
My ReadsRedeem a Gift CardLogout